iBio Announces New Preclinical Data Across Obesity and Cardiometabolic Portfolio at Multiple Scientific Conferences
Key Highlights
- ➤IBIO-610 cut vehicle-adjusted body weight 2.3% from baseline at Week 28
- ➤IBIO-610 lowered total body fat 9.6% versus vehicle at Week 24
- ➤IBIO-610 achieved near-complete Activin E suppression through Week 28
- ➤Amylin receptor agonist reduced lean-rat food intake over 24 hours versus vehicle
- ➤iBio plans further amylin agonist studies in diet-induced obesity models
Expert Statements
Martin Brenner, Chief Executive Officer and Chief Scientific Officer of iBio
“These data demonstrate the power of our AI-enabled antibody discovery platform to generate potent, highly specific molecules against challenging targets.”
Martin Brenner, Chief Executive Officer and Chief Scientific Officer of iBio
“The sustained effects observed in our NHP study strengthen our belief in IBIO-610’s potential to offer a differentiated approach to long-term weight management.”
Martin Brenner, Chief Executive Officer and Chief Scientific Officer of iBio
“Durable Activin E suppression, reductions in fat mass while generally maintaining lean mass, and the newly observed reduction in body weight provide a more comprehensive perspective of how this approach may improve the quality of weight loss.”
Martin Brenner, Chief Executive Officer and Chief Scientific Officer of iBio
“Beyond IBIO-610, our amylin program has taken an important step forward, demonstrating high selectivity for amylin receptors and reduced food intake in a preclinical model.”
Martin Brenner, Chief Executive Officer and Chief Scientific Officer of iBio
“We believe this selective approach has the potential to improve the balance of efficacy and tolerability and look forward to evaluating it in further studies.”
Martin Brenner, Chief Executive Officer and Chief Scientific Officer of iBio
“By pursuing multiple distinct mechanisms, we have the opportunity to build a complementary portfolio of medicines with the potential to extend the cardiometabolic benefits of weight loss beyond current therapies.”
ObesityWeek 2026 data from obese non-human primates showed sustained Activin E suppression and a 2.3% vehicle-adjusted reduction in body weight from baseline with IBIO-610 at week 28.
Amylin program data demonstrating reduced food intake in rats to be presented at PEGS Europe and the Amylin-Based Therapeutics Summit
Get started
Create a free account to read the full story.
